Celladon Corp.'s stock (CLDN) plunged 37% in premarket trade Friday, after the biotechnology company said it will suspend further research or development, and could liquidate the company if it can find a buyer or merger partner. Celladon said the net cash available for distribution to shareholders would be $25 million to $30 million . With 23.91 million shares outstanding, according to FactSet, that implies cash disbursements of $1.05 to $1.25 a share, below the current share price of $1.38 . The company also said about half the jobs that weren't previously cut will be eliminated. "Our employees have been performing with exceptional professionalism under difficult circumstances, and on behalf of the Board I would like to thank them for their efforts," said Chief Executive Paul Cleveland . The stock had tumbled 89% year to date through Thursday's close. - Tomi Kilgore ; 415-439-6400; AskNewswires@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires (END) Dow Jones Newswires 06-26-15 0746ET
The greatest deception men suffer is from their own opinions. ~ Leonardo da Vinci
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.